HIV preexposure prophylaxis for adolescents and young adults
- PMID: 28598901
- PMCID: PMC5762125
- DOI: 10.1097/MOP.0000000000000512
HIV preexposure prophylaxis for adolescents and young adults
Abstract
Purpose of review: The review describes the evidence for HIV preexposure prophylaxis (PrEP) with daily combined tenofovir disoproxil fumarate and emtricitabine for adolescents and young adults. Current recommendations are described, as are the unique medical, socioeconomic, and legal considerations regarding the use of PrEP for youth.
Recent findings: PrEP with daily oral tenofovir disoproxil fumarate-emtricitabine has been shown to help prevent new HIV infection among adults at substantial risk. Evidence suggests a protective benefit of PrEP for youth at risk for HIV, although low adherence is emerging as a barrier to effective use.
Summary: Effective use of antiretrovirals for PrEP represents a seminal development in HIV prevention efforts. Improving access and adherence to PrEP for youth has the potential to substantially reduce the incidence of HIV in this population.
Conflict of interest statement
None.
Similar articles
-
Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.Pharmacotherapy. 2019 Apr;39(4):486-500. doi: 10.1002/phar.2240. Epub 2019 Apr 1. Pharmacotherapy. 2019. PMID: 30815960 Free PMC article. Review.
-
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.JAMA Pediatr. 2017 Nov 1;171(11):1063-1071. doi: 10.1001/jamapediatrics.2017.2007. JAMA Pediatr. 2017. PMID: 28873128 Free PMC article. Clinical Trial.
-
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.Lancet. 2016 Jan 2;387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9. Lancet. 2016. PMID: 26364263 Free PMC article. Clinical Trial.
-
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7. Lancet Infect Dis. 2014. PMID: 25300863 Free PMC article. Clinical Trial.
-
Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Expert Opin Drug Saf. 2016 Sep;15(9):1287-94. doi: 10.1080/14740338.2016.1211108. Epub 2016 Jul 25. Expert Opin Drug Saf. 2016. PMID: 27391203 Review.
Cited by
-
Early disengagement from HIV pre-exposure prophylaxis services and associated factors among female sex workers in Dar es Salaam, Tanzania: a socioecological approach.BMJ Glob Health. 2023 Dec 28;8(12):e013662. doi: 10.1136/bmjgh-2023-013662. BMJ Glob Health. 2023. PMID: 38154811 Free PMC article.
-
A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe.J Int AIDS Soc. 2022 Aug;25(8):e25975. doi: 10.1002/jia2.25975. J Int AIDS Soc. 2022. PMID: 36002910 Free PMC article.
-
Adolescents and Young Adults: The Pediatrician's Role in HIV Testing and Pre- and Postexposure HIV Prophylaxis.Pediatrics. 2022 Jan 1;149(1):e2021055207. doi: 10.1542/peds.2021-055207. Pediatrics. 2022. PMID: 34972226 Free PMC article.
-
HIV pre-exposure prophylaxis: It is time to consider harm reduction care for adolescents in Canada.Paediatr Child Health. 2023 Mar 22;28(6):338-343. doi: 10.1093/pch/pxac115. eCollection 2023 Oct. Paediatr Child Health. 2023. PMID: 37744752 Free PMC article.
-
The Young Adult Centered Healthforce Training (YACHT) Program to Increase HIV Testing and Pre-Exposure Prophylaxis Referrals Among Young Sexual Minority Men in Florida: Protocol for a Type 2 Implementation-Effectiveness Hybrid Trial With a Stepped Wedge Design.JMIR Res Protoc. 2024 Nov 20;13:e63191. doi: 10.2196/63191. JMIR Res Protoc. 2024. PMID: 39566048 Free PMC article.
References
-
- UNICEF. For every child, end AIDS – Seventh stocktaking report. 2016.
-
- US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States: A Clinical Practice Guideline. 2014.
-
- World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2016. These guidelines provide evidence-based guidelines regarding HIV testing, prevention, treatment, and care in a global context. - PubMed
-
- Thigpen MC, Kebaabetswe PM, Paxton La, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med. 2012;367(5):423–34. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous